BRAF and melanoma: Prospective studies with ICB and BRAF/MEKi show comparable response rates in patients with asymptomatic melanoma brain metastasis as compared to patients without CNS involvement; however, once patients become symptomatic or require steroids, ICB becomes less performant [5,6,7,9,26].